Scholarlink

<p>Osteosarcoma is an extremely aggressive malignant tumor, which is quite common among children and has a high rate of disability and mortality. Tripartite Motif Containing 17 (<Emphasis Type="BoldItalic">TRIM17</Emphasis>) is a member of the <Emphasis Type="BoldItalic">TRIM</Emphasis> protein family and exhibits E3 ubiquitin ligase activity. In recent years, <Emphasis Type="BoldItalic">TRIM17</Emphasis> has been implicated in the development of various tumors, particularly in cancer cell clonability and survival potential and drug resistance; however, its regulatory mechanism in osteosarcoma progression remains poorly understood. We found that <Emphasis Type="BoldItalic">TRIM17</Emphasis> was significantly upregulated in osteosarcoma tissues and cells. Survival analysis revealed that <Emphasis Type="BoldItalic">TRIM17</Emphasis> was associated with poor prognosis in osteosarcoma patients. The higher the expression level of <Emphasis Type="BoldItalic">TRIM17</Emphasis>, the worse the prognosis. Its expression was an independent prognostic factor for osteosarcoma patients. The effects of <Emphasis Type="BoldItalic">TRIM17</Emphasis> on osteosarcoma cell clonability and survival potential, migration, and invasion were assessed through phenotypic assays. The results showed that the downregulation of <Emphasis Type="BoldItalic">TRIM17</Emphasis> significantly inhibited osteosarcoma cell clonability and survival potential, migration, and invasion, whereas its overexpression promoted these processes. <Emphasis Type="BoldItalic">FTO</Emphasis> is an m6A methyltransferase and has been identified as a new target for <Emphasis Type="BoldItalic">TRIM17</Emphasis>. Mechanistically, <Emphasis Type="BoldItalic">TRIM17</Emphasis> promotes the ubiquitination and degradation of <Emphasis Type="BoldItalic">FTO</Emphasis> protein, enhances <Emphasis Type="BoldItalic">PDK1</Emphasis> mRNA stability via N6-methyladenosine (m6A) modification, and subsequently promotes phosphorylation-dependent activation of the <Emphasis Type="BoldItalic">AKT/mTOR</Emphasis> signaling pathway, thereby driving osteosarcoma malignancy. In summary, our findings suggest that <Emphasis Type="BoldItalic">TRIM17</Emphasis> may serve as a potential prognostic marker and therapeutic target for osteosarcoma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

TRIM17 promotes the progression of osteosarcoma by regulating PDK1 m6A modification-mediated AKT/mTOR pathway activation through ubiquitination of FTO

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月27日

查看全文
  • Wenda Liu,
  • Di Zheng,
  • Xinghan Huang,
  • Zhun Wei,
  • Zicheng Wei,
  • Weichun Guo

摘要

Osteosarcoma is an extremely aggressive malignant tumor, which is quite common among children and has a high rate of disability and mortality. Tripartite Motif Containing 17 (TRIM17) is a member of the TRIM protein family and exhibits E3 ubiquitin ligase activity. In recent years, TRIM17 has been implicated in the development of various tumors, particularly in cancer cell clonability and survival potential and drug resistance; however, its regulatory mechanism in osteosarcoma progression remains poorly understood. We found that TRIM17 was significantly upregulated in osteosarcoma tissues and cells. Survival analysis revealed that TRIM17 was associated with poor prognosis in osteosarcoma patients. The higher the expression level of TRIM17, the worse the prognosis. Its expression was an independent prognostic factor for osteosarcoma patients. The effects of TRIM17 on osteosarcoma cell clonability and survival potential, migration, and invasion were assessed through phenotypic assays. The results showed that the downregulation of TRIM17 significantly inhibited osteosarcoma cell clonability and survival potential, migration, and invasion, whereas its overexpression promoted these processes. FTO is an m6A methyltransferase and has been identified as a new target for TRIM17. Mechanistically, TRIM17 promotes the ubiquitination and degradation of FTO protein, enhances PDK1 mRNA stability via N6-methyladenosine (m6A) modification, and subsequently promotes phosphorylation-dependent activation of the AKT/mTOR signaling pathway, thereby driving osteosarcoma malignancy. In summary, our findings suggest that TRIM17 may serve as a potential prognostic marker and therapeutic target for osteosarcoma.